Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017 (2017), Article ID 1839809, 7 pages
https://doi.org/10.1155/2017/1839809
Review Article

Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective

Department of Nephrology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Correspondence should be addressed to Feng Wang; moc.361@0301qwzyz and Niansong Wang; moc.361@2102gnosnaingnaw

Received 2 December 2016; Accepted 16 February 2017; Published 13 March 2017

Academic Editor: Carlos Martinez Salgado

Copyright © 2017 Rui Xue et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Chopra and K. K. Sureshkumar, “Co-stimulatory blockade with belatacept in kidney transplantation,” Expert Opinion on Biological Therapy, vol. 14, no. 5, pp. 563–567, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Brenneman, J. Hill, and S. Pullen, “Emerging therapeutics for the treatment of diabetic nephropathy,” Bioorganic and Medicinal Chemistry Letters, vol. 26, no. 18, pp. 4394–4402, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Saran, Y. Li, B. Robinson et al., “US renal data system 2014 annual data report: epidemiology of kidney disease in the United States,” American Journal of Kidney Diseases, vol. 66, no. 1, supplement 1, pp. S1–S305, 2015. View at Google Scholar
  4. P. A. Lopez-Vargas, A. Tong, M. Howell, and J. C. Craig, “Educational interventions for patients with CKD: a systematic review,” American Journal of Kidney Diseases, vol. 68, no. 3, pp. 353–370, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Uhlig, J. S. Berns, S. Carville et al., “Recommendations for kidney disease guideline updating: a report by the KDIGO Methods Committee,” Kidney International, vol. 89, no. 4, pp. 753–760, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. I. H. De Boer, T. C. Rue, Y. N. Hall, P. J. Heagerty, N. S. Weiss, and J. Himmelfarb, “Temporal trends in the prevalence of diabetic kidney disease in the United States,” The Journal of the American Medical Association, vol. 305, no. 24, pp. 2532–2539, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. “KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease,” American Journal of Kidney Diseases, vol. 49, no. 2, supplement 2, pp. S12–S154, 2007. View at Publisher · View at Google Scholar
  8. K. R. Tuttle, G. L. Bakris, R. W. Bilous et al., “Diabetic kidney disease: a report from an ADA consensus conference,” Diabetes Care, vol. 37, no. 10, pp. 2864–2883, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. H. Ahn, J. H. Yu, S.-H. Ko et al., “Prevalence and determinants of diabetic nephropathy in Korea: Korea National Health and Nutrition examination survey,” Diabetes and Metabolism Journal, vol. 38, no. 2, pp. 109–119, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Irannejad, A. Ghajar, M. Afarideh et al., “Association of peripheral nesfatin-1 with early stage diabetic nephropathy,” Pathophysiology, 2016. View at Publisher · View at Google Scholar
  11. S. Katayama, D. Yamada, M. Nakayama et al., “A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy,” Journal of Diabetes and Its Complications, 2016. View at Publisher · View at Google Scholar
  12. M. Fouad, H. Fathy, and A. Zidan, “Serum uric acid and its association with hypertension, early nephropathy and chronic kidney disease in type 2 diabetic patients,” Jornal Brasileiro de Nefrologia, vol. 38, no. 4, pp. 403–410, 2016. View at Publisher · View at Google Scholar
  13. P. I. Machingura, V. Chikwasha, P. N. Okwanga, and E. Gomo, “Prevalence of and factors associated with nephropathy in diabetic patients attending an outpatient clinic in Harare, Zimbabwe,” The American Journal of Tropical Medicine and Hygiene, vol. 96, no. 2, pp. 477–482, 2017. View at Publisher · View at Google Scholar
  14. A. Perkowska-Ptasinska, D. Deborska-Materkowska, A. Bartczak et al., “Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland,” BMC Nephrology, vol. 17, article 194, 2016. View at Publisher · View at Google Scholar
  15. G. Kaidonis, M. C. Gillies, S. Abhary et al., “A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients,” Acta Diabetologica, vol. 53, no. 4, pp. 643–650, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Li, Y. Chen, J. Liu et al., “Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial,” PLoS ONE, vol. 10, no. 5, Article ID e0126027, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 37, supplement 1, pp. S81–S90, 2013. View at Publisher · View at Google Scholar
  18. W. Yang, J. Lu, J. Weng et al., “Prevalence of diabetes among men and women in China,” The New England Journal of Medicine, vol. 362, no. 12, pp. 1090–1101, 2010. View at Publisher · View at Google Scholar
  19. L. Wang, M. Zhou, T. Astell-Burt et al., “Geographical variation in diabetes prevalence and detection in China: multilevel spatial analysis of 98,058 adults,” Diabetes Care, vol. 38, no. 1, pp. 72–81, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Zhang, F. Wang, L. Wang et al., “Prevalence of chronic kidney disease in China: a cross-sectional survey,” The Lancet, vol. 379, no. 9818, pp. 815–822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Liu, “Nephrology in China,” Nature Reviews Nephrology, vol. 9, no. 9, pp. 523–528, 2013. View at Publisher · View at Google Scholar
  22. S. Dagogo-Jack and J. V. Santiago, “Pathophysiology of Type 2 diabetes and modes of action of therapeutic interventions,” Archives of Internal Medicine, vol. 157, no. 16, pp. 1802–1817, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Dagogo-Jack, “Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management,” Journal of the National Medical Association, vol. 95, no. 9, pp. 774–789, 2003. View at Google Scholar · View at Scopus
  24. L. S. Stryker, “Modifying risk factors: strategies that work diabetes mellitus,” Journal of Arthroplasty, vol. 31, no. 8, pp. 1625–1627, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Matsusaka, E. Sandgren, A. Shintani et al., “Podocyte injury damages other podocytes,” Journal of the American Society of Nephrology, vol. 22, no. 7, pp. 1275–1285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Barisoni and P. Mundel, “Podocyte biology and the emerging understanding of podocyte diseases,” American Journal of Nephrology, vol. 23, no. 5, pp. 353–360, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Greka and P. Mundel, “Cell biology and pathology of podocytes,” Annual Review of Physiology, vol. 74, pp. 299–323, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Mundel and J. Reiser, “Proteinuria: an enzymatic disease of the podocyte,” Kidney International, vol. 77, no. 7, pp. 571–580, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Peti-Peterdi and A. Sipos, “A high-powered view of the filtration barrier,” Journal of the American Society of Nephrology, vol. 21, no. 11, pp. 1835–1841, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Bressler and D. G. Johnson, “Pharmacological regulation of blood glucose levels in non-insulin- dependent diabetes mellitus,” Archives of Internal Medicine, vol. 157, no. 8, pp. 836–848, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. A. L. Harrison, N. Shields, N. F. Taylor, and H. C. Frawley, “Exercise improves glycaemic control in women diagnosed with gestational diabetes mellitus: a systematic review,” Journal of Physiotherapy, vol. 62, no. 4, pp. 188–196, 2016. View at Publisher · View at Google Scholar
  32. S. G. Schorr, H.-P. Hammes, U. A. Müller, H.-H. Abholz, R. Landgraf, and B. Bertram, “The prevention and treatment of retinal complications in diabetes,” Deutsches Ärzteblatt International, vol. 113, no. 48, pp. 816–823, 2016. View at Google Scholar
  33. P. Fioretto, “Renal protection in diabetes: role of glycemic control,” Journal of the American Society of Nephrology, vol. 17, no. 4, supplement 2, pp. S86–S89, 2006. View at Publisher · View at Google Scholar
  34. F. Ismail-Beigi, T. Craven, M. A. Banerji et al., “Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial,” The Lancet, vol. 376, no. 9739, pp. 419–430, 2010. View at Publisher · View at Google Scholar
  35. W. Pimenta, M. Korytkowski, W. Evron et al., “Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative,” JAMA: The Journal of the American Medical Association, vol. 273, no. 23, pp. 1855–1861, 1995. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Ba, P. Han, G. Yuan et al., “Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin,” Journal of Diabetes, 2016. View at Publisher · View at Google Scholar
  37. S. E. Inzucchi, D. G. Maggs, G. R. Spollett et al., “Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus,” New England Journal of Medicine, vol. 338, no. 13, pp. 867–872, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. M. K. Cavaghan, D. A. Ehrmann, M. M. Byrne, and K. S. Polonsky, “Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance,” The Journal of Clinical Investigation, vol. 100, no. 3, pp. 530–537, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. W. J. Malaisse and P. Lebrun, “Mechanisms of sulfonylurea-induced insulin release,” Diabetes Care, vol. 13, supplement 3, pp. 9–17, 1990. View at Google Scholar · View at Scopus
  40. T. Y. Nelson, K. L. Gaines, A. S. Rajan, M. Berg, and A. E. Boyd III, “Increased cytosolic calcium. A signal for sulfonylurea-stimulated insulin release from beta cells,” Journal of Biological Chemistry, vol. 262, no. 6, pp. 2608–2612, 1987. View at Google Scholar · View at Scopus
  41. O. G. Kolterman, R. S. Gray, G. Shapiro, J. A. Scarlett, J. Griffin, and J. M. Olefsky, “The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects,” Diabetes, vol. 33, no. 4, pp. 346–354, 1984. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Ravindran, V. Kuruvilla, K. Wilbur, and S. Munusamy, “Nephroprotective effects of metformin in diabetic nephropathy,” Journal of Cellular Physiology, vol. 232, no. 4, pp. 731–742, 2017. View at Publisher · View at Google Scholar
  43. S. Gu, Y. Zeng, D. Yu, X. Hu, H. Dong, and C. Hu, “cost-effectiveness of saxagliptin versus acarbose as second-line therapy in type 2 diabetes in China,” PLOS ONE, vol. 11, no. 11, p. e0167190, 2016. View at Publisher · View at Google Scholar
  44. R. A. DeFronzo and M. Abdul-Ghani, “Type 2 diabetes can be prevented with early pharmacological intervention,” Diabetes Care, vol. 34, no. S2, pp. S202–S209, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Eknoyan, T. Hostetter, G. L. Bakris et al., “Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),” American Journal of Kidney Diseases, vol. 42, no. 4, pp. 617–622, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Futrakul and P. Futrakul, “Therapeutic resistance to ACEI and ARB combination in macroalbuminuric diabetic nephropathy,” Clinical Nephrology, vol. 78, no. 3, p. 250, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Ren, L. Tang, Y. Cai et al., “Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy,” Renal Failure, vol. 37, no. 4, pp. 548–561, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. A. S. Bomback, A. V. Kshirsagar, M. A. Amamoo, and P. J. Klemmer, “Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review,” American Journal of Kidney Diseases, vol. 51, no. 2, pp. 199–211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Chogtu, R. Magazine, and K. L. Bairy, “Statin use and risk of diabetes mellitus,” World Journal of Diabetes, vol. 6, no. 2, pp. 352–357, 2015. View at Google Scholar
  50. C. R. Sirtori, “The pharmacology of statins,” Pharmacological Research, vol. 88, pp. 3–11, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Chogtu, R. Magazine, and K. L. Bairy, “Response to comment on: statin use and risk of diabetes mellitus,” World Journal of Diabetes, vol. 7, no. 18, pp. 481–482, 2016. View at Publisher · View at Google Scholar
  52. H. Sternlicht and G. L. Bakris, “Management of hypertension in diabetic nephropathy: how low should we go?” Blood Purification, vol. 41, no. 1–3, pp. 139–143, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. G. L. Bakris, M. R. Weir, S. Shanifar et al., “Effects of blood pressure level on progression of diabetic nephropathy: Results from The RENAAL Study,” Archives of Internal Medicine, vol. 163, no. 13, pp. 1555–1565, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. K. J. Schjoedt, K. Rossing, T. R. Juhl et al., “Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy,” Kidney International, vol. 70, no. 3, pp. 536–542, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Zhou, F. Lu, K. Cao, D. Xu, D. Goltzman, and D. Miao, “Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice,” Kidney International, vol. 74, no. 2, pp. 170–179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. M. R. Haussler, “Vitamin D receptors: nature and function,” Annual Review of Nutrition, vol. 6, pp. 527–562, 1986. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Yuan, W. Pan, J. Kong et al., “1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter,” Journal of Biological Chemistry, vol. 282, no. 41, pp. 29821–29830, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Larsson, U. Nisbeth, Ö. Ljunggren, H. Jüppner, and K. B. Jonsson, “Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers,” Kidney International, vol. 64, no. 6, pp. 2272–2279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Fligny, M. Barton, and P.-L. Tharaux, “Endothelin and podocyte injury in chronic kidney disease,” Contributions to nephrology, vol. 172, pp. 120–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. L. L. Baggio and D. J. Drucker, “Biology of incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. M. M. Sousa, S. D. Yan, D. Stern, and M. J. Saraiva, “Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation,” Laboratory Investigation, vol. 80, no. 7, pp. 1101–1110, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. T. K. Wöbke, B. L. Sorg, and D. Steinhilber, “Vitamin D in inflammatory diseases,” Frontiers in Physiology, vol. 5, article 244, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. C. G. Liew and P. W. Andrews, “Stem cell therapy to treat diabetes mellitus,” Review of Diabetic Studies, vol. 5, no. 4, pp. 203–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. A. H. Hamza, W. M. Al-Bishri, L. A. Damiati, and H. H. Ahmed, “Mesenchymal stem cells: a future experimental exploration for recession of diabetic nephropathy,” Renal Failure, vol. 39, no. 1, pp. 67–76, 2016. View at Publisher · View at Google Scholar
  65. A. J. Peired, A. Sisti, and P. Romagnani, “Renal cancer stem cells: characterization and targeted therapies,” Stem Cells International, vol. 2016, Article ID 8342625, 12 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Baban, J. Y. Liu, S. Payne, W. Abebe, J. C. Yu, and M. S. Mozaffari, “Status of stem cells in diabetic nephropathy: predictive and preventive potentials,” EPMA Journal, vol. 7, no. 1, p. 21, 2016. View at Publisher · View at Google Scholar
  67. L. J. Hickson, A. Eirin, and L. O. Lerman, “Challenges and opportunities for stem cell therapy in patients with chronic kidney disease,” Kidney International, vol. 89, no. 4, pp. 767–778, 2016. View at Publisher · View at Google Scholar · View at Scopus
  68. M. E. Ezquer, F. E. Ezquer, M. L. Arango-Rodríguez, and P. A. Conget, “MSC transplantation: a promising therapeutic strategy to manage the onset and progression of diabetic nephropathy,” Biological Research, vol. 45, no. 3, pp. 289–296, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Wang, H. Huang, P. Liu et al., “Inhibition of phosphorylation of p38 MAPK involved in the protection of nephropathy by emodin in diabetic rats,” European Journal of Pharmacology, vol. 553, no. 1–3, pp. 297–303, 2006. View at Publisher · View at Google Scholar · View at Scopus
  70. W. Y. Pei, C. H. Yang, and X. L. Zhang, “Effects and mechanism of Tripterygium wilfordii on chronic glomerulo nephritis,” Genetics and Molecular Research, vol. 15, no. 1, Article ID 15017410, 2016. View at Publisher · View at Google Scholar · View at Scopus
  71. D. Gui, L. Wei, G. Jian, Y. Guo, J. Yang, and N. Wang, “Notoginsenoside R1 ameliorates podocyte adhesion under diabetic condition through α3β1 integrin upregulation in vitro and in vivo,” Cellular Physiology and Biochemistry, vol. 34, no. 6, pp. 1849–1862, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Chen, D. Gui, J. Chen, D. He, Y. Luo, and N. Wang, “Down-regulation of PERK-ATF4-CHOP pathway by astragaloside IV is associated with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis in diabetic rats,” Cellular Physiology and Biochemistry, vol. 33, no. 6, pp. 1975–1987, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Xiang, P. Jiang, L. Zhou et al., “Additive effect of qidan dihuang grain, a traditional chinese medicine, and angiotensin receptor blockers on albuminuria levels in patients with diabetic nephropathy: a randomized, parallel-controlled trial,” Evidence-based Complementary and Alternative Medicine, vol. 2016, Article ID 1064924, 8 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Y. Ou, D. Huang, Y. S. Wu et al., “A meta-analysis of randomized controlled trials of yiqi yangyin huoxue method in treating diabetic nephropathy,” Evidence-Based Complementary and Alternative Medicine, vol. 2016, Article ID 3257603, 12 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  75. Z. Rahimi, “The role of renin angiotensin aldosterone system genes in diabetic nephropathy,” Canadian Journal of Diabetes, vol. 40, no. 2, pp. 178–183, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. C. M. Lawes, S. V. Hoorn, and A. Rodgers, “Global burden of blood-pressure-related disease, 2001,” The Lancet, vol. 371, no. 9623, pp. 1513–1518, 2008. View at Publisher · View at Google Scholar · View at Scopus